New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis (Q34196968)

31 July 2017

0 references

1 reference

title

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis (English)

1 reference

31 July 2017

0 references

1 reference

Kristian Wahlbeck

2

0 references

Werner Kissling

series ordinal

4

object named as

Werner Kissling

1 reference

31 July 2017

1

Stefan Leucht

1 reference

31 July 2017

Johannes Hamann

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

31 July 2017

1 reference

31 July 2017

volume

361

1 reference

31 July 2017

issue

9369

1 reference

31 July 2017

page(s)

1581-1589

1 reference

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

The efficacy of zotepine in schizophrenia: A meta-analysis of BPRS and improvement scale scores.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Clozapine in China: a review and preview of US/PRC collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

Content and quality of 2000 controlled trials in schizophrenia over 50 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913306-5

7 January 2021

10.1016/S0140-6736(03)13306-5

Identifiers

DOI

1 reference

31 July 2017

1 reference